ArticleApplied health economics and health policy2021

Budget Impact Analysis of the Introduction of Subcutaneous Infliximab (CT-P13 SC) for the Treatment of Rheumatoid Arthritis in the United Kingdom.

Han Geul Byun et al.PubMed ↗Publisher ↗

No numbers read from the abstract.